A weekly sweep of the medical literature, regulatory filings, company announcements and trade press, matched against your terms and your companies, and delivered as a short brief with a link to every original.
Every week it reads the nephrology literature, preprints, FDA and EMA actions, clinical trial registries, the Federal Register, press releases from every company on your list, and the trade press. Not a keyword alert pointed at Google. Separate connections to each kind of source, because a journal and a press release do not work the same way.
A single piece of news usually arrives three or four times: the company says it, a reporter covers it, and the underlying paper publishes. You get one entry with all the links, not four items that look like four stories.
Three or four sentences on what happened and one line on why it matters, written from the source material and checked back against it before anything goes out. Tagged with the terms and companies from your list that it actually hit.
Your own Medicare claims analysis, picked up the day it published. Three days later the tool caught the ESC and ERA joint guideline calling for universal CKD screening, which makes almost exactly the same argument from the cardiology side.
This one arrived three separate times: the eGenesis press release, STAT's coverage, and the underlying paper in The Lancet. One entry, three links, one summary.
A 74-patient randomized pilot in CJASN. The kind of finding that never makes the trade press and goes straight into patient education material.
The FDA took no action in kidney disease across the entire window. The European regulator does not meet in August. No CMS or transplant policy moved. So the brief has a section that says exactly that, along with anything it tried to reach and could not.
A brief that quietly leaves out the slow parts starts to look broken after a month. One that tells you what it checked is a brief you can actually rely on.